Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes.

Mayyas F

Journal of diabetes and its complications21 Jun 2026

PMID42341385DOI10.1016/j.jdiacomp.2026.109362PepBankPUB-42341385

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study28

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide treatment reduced glucose levels.
In plain wordsIn rats with diabetes, liraglutide reduced glucose levels.
Peptide
Liraglutide
Outcome
DecreaseGlucose levels
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Dapagliflozin and/or liraglutide treatments reduced glucose levels, with the strongest reduction in the combined group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide did not alter the kidney-to-body weight ratio.
In plain wordsIn rats with diabetes, liraglutide did not change kidney-to-body weight ratio.
Peptide
Liraglutide
Outcome
No significant changeKidney-to-body weight ratio
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Diabetes increased kidney-to-body weight ratio, which was not altered by any treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138503
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide normalized renal C-reactive protein levels.
In plain wordsIn rats with diabetes, liraglutide normalized kidney C-reactive protein levels.
Peptide
Liraglutide
Outcome
DecreaseRenal C-reactive protein
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Liraglutide normalized levels of CRP and TNF-α, though adding dapagliflozin provided no additional improvement.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138504
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide normalized renal tumor necrosis factor-alpha levels.
In plain wordsIn rats with diabetes, liraglutide normalized kidney tumor necrosis factor-alpha levels.
Peptide
Liraglutide
Outcome
DecreaseRenal tumor necrosis factor-alpha
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Liraglutide normalized levels of CRP and TNF-α, though adding dapagliflozin provided no additional improvement.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138505
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide did not change renal interleukin-6 levels.
In plain wordsIn rats with diabetes, liraglutide did not change kidney interleukin-6 levels.
Peptide
Liraglutide
Outcome
No significant changeRenal interleukin-6
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138508
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide did not change renal thiobarbituric acid reactive substances.
In plain wordsIn rats with diabetes, liraglutide did not change kidney oxidative-stress markers.
Peptide
Liraglutide
Outcome
No significant changeRenal thiobarbituric acid reactive substances
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138509
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide did not change renal glutathione peroxidase levels.
In plain wordsIn rats with diabetes, liraglutide did not change kidney glutathione peroxidase.
Peptide
Liraglutide
Outcome
No significant changeRenal glutathione peroxidase
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138510
08AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide reduced renal nitric oxide.
In plain wordsIn rats with diabetes, liraglutide reduced kidney nitric oxide.
Peptide
Liraglutide
Outcome
DecreaseRenal nitric oxide
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138511
09AnimalAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, liraglutide normalized renal fibrosis.
In plain wordsIn rats with diabetes, liraglutide normalized kidney fibrosis.
Peptide
Liraglutide
Outcome
DecreaseRenal fibrosis
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Liraglutide, but not dapagliflozin, normalized renal fibrosis, tumor growth factor-β, and collagen type IV.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased renal fibrosis.
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138512
10AnimalAnimal study (in vivo)Mechanism
In rats with streptozotocin-induced diabetes, liraglutide normalized renal tumor growth factor-beta.
In plain wordsIn rats with diabetes, liraglutide normalized kidney tumor growth factor-beta.
Peptide
Liraglutide
Outcome
Direction not reportedRenal tumor growth factor-beta
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Liraglutide, but not dapagliflozin, normalized renal fibrosis, tumor growth factor-β, and collagen type IV.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138513
11AnimalAnimal study (in vivo)Mechanism
In rats with streptozotocin-induced diabetes, liraglutide normalized renal collagen type IV.
In plain wordsIn rats with diabetes, liraglutide normalized kidney collagen type IV.
Peptide
Liraglutide
Outcome
Direction not reportedRenal collagen type IV
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (Wistar rat).
Source sentences
Summary
Liraglutide, but not dapagliflozin, normalized renal fibrosis, tumor growth factor-β, and collagen type IV.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
Report a problemFND-4234138514

Studies that did not test the peptide alone17

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

12AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide reduced glucose levels, with the strongest reduction in the combined group.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide reduced glucose levels most.
Peptide
Liraglutide
Outcome
DecreaseGlucose levels
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Dapagliflozin and/or liraglutide treatments reduced glucose levels, with the strongest reduction in the combined group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138502
13AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, adding dapagliflozin to liraglutide did not further improve renal C-reactive protein versus liraglutide alone.
In plain wordsIn diabetic rats, adding dapagliflozin to liraglutide did not further improve kidney C-reactive protein versus liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeRenal C-reactive protein
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
Liraglutide alone
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
Liraglutide normalized levels of CRP and TNF-α, though adding dapagliflozin provided no additional improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138506
14AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, adding dapagliflozin to liraglutide did not further improve renal tumor necrosis factor-alpha versus liraglutide alone.
In plain wordsIn diabetic rats, adding dapagliflozin to liraglutide did not further improve kidney TNF-alpha versus liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeRenal tumor necrosis factor-alpha
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
Liraglutide alone
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
Liraglutide normalized levels of CRP and TNF-α, though adding dapagliflozin provided no additional improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138507
15AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide did not alter the kidney-to-body weight ratio.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide did not change kidney-to-body weight ratio.
Peptide
Liraglutide
Outcome
No significant changeKidney-to-body weight ratio
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Diabetes increased kidney-to-body weight ratio, which was not altered by any treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138515
16AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide did not change renal interleukin-6 levels.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide did not change kidney interleukin-6 levels.
Peptide
Liraglutide
Outcome
No significant changeRenal interleukin-6
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138516
17AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide did not change renal thiobarbituric acid reactive substances.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide did not change kidney oxidative-stress markers.
Peptide
Liraglutide
Outcome
No significant changeRenal thiobarbituric acid reactive substances
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138517
18AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide did not change renal glutathione peroxidase levels.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide did not change kidney glutathione peroxidase levels.
Peptide
Liraglutide
Outcome
No significant changeRenal glutathione peroxidase
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138518
19AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats with streptozotocin-induced diabetes, dapagliflozin plus liraglutide reduced renal nitric oxide.
In plain wordsIn rats with diabetes, dapagliflozin plus liraglutide reduced kidney nitric oxide.
Peptide
Liraglutide
Outcome
DecreaseRenal nitric oxide
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
None of the treatments changed renal levels of IL-6, TBARS, and GPx levels, however, all reduced nitric oxide.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138519
20AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased the kidney-to-body weight ratio versus controls.
In plain wordsIn rats, diabetes increased the kidney-to-body weight ratio compared with controls.
Peptide
Liraglutide
Outcome
IncreaseKidney-to-body weight ratio
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Diabetes increased kidney-to-body weight ratio, which was not altered by any treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138520
21AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased renal C-reactive protein versus controls.
In plain wordsIn rats, diabetes increased kidney C-reactive protein compared with controls.
Peptide
Liraglutide
Outcome
IncreaseRenal C-reactive protein
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138521
22AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased renal tumor necrosis factor-alpha versus controls.
In plain wordsIn rats, diabetes increased kidney tumor necrosis factor-alpha compared with controls.
Peptide
Liraglutide
Outcome
IncreaseRenal tumor necrosis factor-alpha
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138522
23AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased renal interleukin-6 versus controls.
In plain wordsIn rats, diabetes increased kidney interleukin-6 compared with controls.
Peptide
Liraglutide
Outcome
IncreaseRenal interleukin-6
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138523
24AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased renal thiobarbituric acid reactive substances versus controls.
In plain wordsIn rats, diabetes increased kidney thiobarbituric acid reactive substances compared with controls.
Peptide
Liraglutide
Outcome
IncreaseRenal thiobarbituric acid reactive substances
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138524
25AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes did not change renal endothelin-1 versus controls.
In plain wordsIn rats, diabetes did not change kidney endothelin-1 compared with controls.
Peptide
Liraglutide
Outcome
No significant changeRenal endothelin-1
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138525
26AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes did not change renal monocyte chemoattractant protein-1 versus controls.
In plain wordsIn rats, diabetes did not change kidney monocyte chemoattractant protein-1 compared with controls.
Peptide
Liraglutide
Outcome
No significant changeRenal monocyte chemoattractant protein-1
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138526
27AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes did not change renal glutathione peroxidase versus controls.
In plain wordsIn rats, diabetes did not change kidney glutathione peroxidase compared with controls.
Peptide
Liraglutide
Outcome
No significant changeRenal glutathione peroxidase
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Oxidative stress · Kidney and urinary
Source sentences
Summary
DM increased renal inflammatory and oxidant markers, including C-reactive Protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thiobarbituric acid reactive substances (TBARS) without altering levels of endothelin-1, Monocyte chemoattractant protein-1 (MCP-1) and glutathione peroxidase (GPx).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138527
28AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In Wistar rats, streptozotocin-induced diabetes increased renal fibrosis versus controls.
In plain wordsIn rats, diabetes increased kidney fibrosis compared with controls.
Peptide
Liraglutide
Outcome
IncreaseRenal fibrosis
Study
Wistar ratn: not reported in source
streptozotocin-induced diabetes
Comparator
controls
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
DM increased renal fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult Wistar rats were divided into five groups (15-17 rats/group): control; diabetes (DM, single intraperitoneal STZ 50 mg/kg); dapagliflozin-treated diabetes (Dapa, 1 mg/kg orally); liraglutide-treated diabetes (Lira, 0.4 mg/kg subcutaneously); and combined treatment (Dapa+Lira).
Summary · context
Treatments were administered for 8 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4234138528

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.